Can Moderna Win the Race to Find a COVID-19 Vaccine?

With a significant portion of the world still in lockdown due to the COVID-19 pandemic, many investors are anxious about how soon a vaccine can be developed to combat the coronavirus. Currently, one of the most promising candidates for this challenge is Moderna's (NASDAQ: MRNA) mRNA-1273 vaccine.

Although there's a high degree of optimism surrounding the stock, there is no easy path to victory in the battle against this deadly pandemic. Today, let's take a look at some of the challenges the company has to face in its clinical investigation, and whether it's likely to overcome them.